Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

BACKGROUND: The immunomodulation of the antitumor response driven by immunocheckpoint inhibitors (ICIs) such as PD-L1 (Programmed Death Ligand-1) monoclonal antibody (α-PD-L1) have shown relevant clinical outcomes in a subset of patients. This fact has led to the search for rational combinations wit...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Nanobiotechnology
Main Authors: Merino, María, Lozano, Teresa, Casares, Noelia, Lana, Hugo, Troconiz, Iñaki F., ten Hagen, Timo L. M., Kochan, Grazyna, Berraondo, Pedro, Zalba, Sara, Garrido, María J.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8042980/
https://ncbi.nlm.nih.gov/pubmed/33849551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12951-021-00846-z
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki